Search

Search Constraints

You searched for: Author/Creator Bruns, Rolf

Search Results

1. SYST-06 INTRACRANIAL ACTIVITY OF TEPOTINIB IN PATIENTS WITH MET EXON 14 (METEX14) SKIPPING NSCLC ENROLLED IN VISION. (5th August 2022)

2. Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: results from the VISION study and local UK experience. (March 2022)

3. Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study. (25th May 2021)

4. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. Issue 11 (November 2020)

5. TRLS-03. Intracranial activity of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC enrolled in VISION. (9th August 2021)